Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (471-480 of 583) with videos related to

Pageof 59
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Leukemia|June 7, 2018
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcomeAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid LeukemiaMarius Bill, Aparna Pathmanathan, Malith Karunasiri, et al.
Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Pageof 59

Showing results (471-480 of 583) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Leukemia|June 7, 2018
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcomeAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid LeukemiaMarius Bill, Aparna Pathmanathan, Malith Karunasiri, et al.
Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Pageof 59